|
EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs
Drugmakers evaluating multiple sclerosis treatments for the EU should use relapse rate as the primary efficacy parameter in clinical trials for relapsing-remitting MS or secondary progressive MS with superimposed relapses, according to a draft European Medicines Agency (EMA) guideline.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives